Skip to main content
AA

Anivance AI

Paitent on Chips develops microfluidic "organ-on-a-chip" systems that simulate human organ functions for drug discovery and development. These platforms enable researchers to test drug efficacy and toxicity in a more physiologically relevant environment than traditional cell cultures, accelerating preclinical research.

Founded 202413100+ followers
Updated 3 months ago

Funding

$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Traditional drug discovery methods often rely on animal testing or simplified cell cultures, which fail to accurately replicate human organ functions and predict drug efficacy or toxicity in humans. This leads to high preclinical failure rates and inefficient R&D processes.

Solution

Anivance AI offers an AI-driven biotechnology platform that uses microfluidic "organ-on-a-chip" systems to simulate human organ functions for drug discovery and development. The platform integrates AI agents into automated research workflows, enabling pharmaceutical companies to make faster, smarter, and more data-driven decisions. The system supports the construction of complex, multi-tissue models that replicate organ-level functions and provides insights into drug Mechanism of Action (MOA). By embedding AI agents into automated research workflows, the platform optimizes experiment design, mechanistic analysis, and real-time data interpretation.

Target Audience

The primary customers are pharmaceutical companies, biotech companies, and clinical institutions seeking to accelerate preclinical testing, improve R&D efficiency, and reduce preclinical failure rates.

Features

  • AI agent-powered organ-on-chip (OoC) technology for simulating human organ functions
  • Scalable platform for biomimetic organ modeling and multi-cellular interactions
  • Real-time sensing and high-resolution electrophysiological signals for rapid drug screening
  • High-throughput screening capabilities designed to integrate with automated culture systems
  • AI modules that drive every stage of experimentation, from protocol generation to real-time monitoring and data analysis
  • Standardized workflows for constructing complex, multi-tissue models
  • AI-driven analytics for experiment design, mechanistic analysis (MOA), and real-time data interpretation
This profile is AI-generated and may contain inaccuracies.